Trauma remains a major cause of mortality and morbidity. 10% of blunt force trauma patients admitted to a major trauma centre will have sustained one or more fractured ribs, which may cause significant pain and problems with breathing.
To establish the outcome of rib fractures and their treatments it is important to know what to measure, and how to measure this accurately. A patient reported outcome measure (PROM) is a questionnaire used to measure patient reported outcomes, to show how the patient is doing from their perspective.
Whilst there is ongoing interest in surgery to fix broken ribs, there is no PROM specifically designed for patients with broken ribs following chest trauma. Therefore, it is not clear whether the symptoms that are most important to these patients are being represented by the current outcome measures. This study aims to create a PROM specific to rib fracture patients to give us a better understanding of whether a new treatment actually makes a difference to the patient’s recovery.
The 1st part of the study involves asking patients with rib fractures to help design a new PROM. This will be conducted through focus groups at a site in Nottingham. The 2nd part of the study entails field testing, whereby patients with rib fractures will be asked to test this new PROM. This will be conducted across multiple secondary care settings in the UK, including the Royal Infirmary of Edinburgh. The study is expected to run for approximately 2 years, with recruitment targets of 50 patients for the PROM Creation phase and 250 for the Field Testing phase.
The purpose of this study is to test a new vaccine, ChAdOx1 nCoV-19, against COVID-19 in healthy volunteers.
The ChAdOx1 nCoV-19 vaccine has been developed in Oxford in an effort to protect healthy people from the pandemic. This study will evaluate the safety of the vaccine and its ability to generate an immune response against the virus.
This is a randomised trial. Participants will be randomly allocated to receive either the ChAdOx1 nCoV-19 vaccine, or a Men ACWY (meningitus vaccine). Volunteers will not be told which vaccine they will receive.
Participants will be asked to return for 6 visits across 12 months to evaluate their health.
Across the UK the trial aims to recruit 10,260 volunteers.
If you are interested in taking part, please click on this link and complete the online questionnaire: https://www.covid19vaccinetrial.co.uk/participate-edinburgh
The purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers.